This protocol covers the management of suspected or confirmed meningococcal disease in patients who do not have a severe allergy to beta-lactam antibiotics — including penicillin, amoxicillin, or cephalosporins.
Clinical scenario: Suspected or confirmed meningococcal disease in a patient without a severe beta-lactam allergy. Where an allergy is reported, clarifying its nature is essential — a non-severe reaction may still permit use of the first-line approach.
Management centres on prompt intravenous antibiotic therapy. The choice of agent and the patient's allergy history are closely linked in this scenario.
Clinical goal: Recovery from meningococcal disease within the expected treatment period. If the expected response is not achieved, advice from an infection specialist is recommended.
Therefore, the committee agreed that clinicians should seek information about the nature of the allergy, and ceftriaxone should still be considered if the nature of the allergic reaction they get is not severe, in accordance with the first line treatment recommended above.
Given the limitations of the evidence, the committee agreed to make recommendations based on their clinical knowledge and experience, and on current practice, and recommended intravenous ceftriaxone for the treatment of suspected or confirmed meningococcal disease.
The committee recommended that people with meningococcal disease should be treated for 5 days with ceftriaxone.
The committee agreed that advice from an infection specialist should be sought if the person had not recovered after 5 days.
View source ↗